You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKinsey
Express Scripts
Moodys
AstraZeneca

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,047,202


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,047,202 protect, and when does it expire?

Patent 8,047,202 protects ONZETRA XSAIL and is included in one NDA.

This patent has five patent family members in three countries.

Summary for Patent: 8,047,202
Title:Nasal devices
Abstract: A nasal delivery device and a method of delivering substance to a nasal airway of a subject, can be used for mass treatment, especially mass vaccination. The delivery device can include an interface unit, as a replaceable unit, having at least one nosepiece unit for fitting to a respective nostril of a subject, a nozzle from which substance is in use delivered, and at least one delivery unit having a substance supply unit for delivering substance to the nozzle of the at least one nosepiece unit. The delivery device can also include an actuation unit for actuating the at least one delivery unit of the interface unit.
Inventor(s): Djupesland; Per Gisle (Oslo, NO)
Assignee: OptiNose AS (Oslo, NO)
Application Number:12/339,716
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,047,202

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,047,202

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0215270.0Jul 2, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Mallinckrodt
McKinsey
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.